A molecular model of the F12 biotherapy shows the fold of its polypeptide backbone. Residual T-cell epitopes are mapped onto the structure and colored from white (no epitopes) to dark red (dense overlapping epitopes). The muted red coloring indicates that T-cell epitopes have been broadly silenced in the engineered F12 variant, and this reduced epitope content underlies the molecule’s improved safety and efficacy profile.
The Centers for Disease Control and Prevention (CDC) has prioritized finding effective treatment of methicillin-resistant Staphylococcus aureus (MRSA), one of the most common bacterial pathogens and the single most deadly drug-resistant bacteria in the United States. Now, a new study led by Dartmouth engineering researchers shows promise for an engineered lysin-based antibacterial agent that may enable safe, repeated dosing to treat life-threatening infections by MRSA and other types of S. aureus.
In recent years, lysins—enzymes naturally produced by microbes and associated viruses—have shown potential to treat S. aureus, which can rapidly acquire resistance to other types of antibiotic drugs.
“Lysins are one of the most promising next-generation antibiotics. They kill drug-sensitive and drug-resistant bacteria with equal efficacy, they can potentially suppress new resistance phenotypes, and they also have this laser-like precision,” said Dartmouth engineering professor and corresponding author Karl Griswold.
While there is promise in lysins, development has been slowed due to concerns that they prompt humans’ immune systems to develop antidrug antibodies, which can have negative side effects including life-threatening hypersensitivity reactions.
That’s why the Dartmouth engineering team—which also included researchers in Dartmouth’s computer science department, The Lundquist Institute at Harbor-UCLA Medical Center, Lyticon, and Stealth Biologics—engineered and patented F12, a new lysin-based antibacterial agent. F12 is essentially able to hide from the human immune system (due to T cell epitope deletion), and therefore does not cause the same negative side effects as unmodified, natural lysins.
F12 is the first lysin-based treatment with the potential to be used multiple times on a single patient, making it ideal to treat particularly persistent drug-resistant and drug-sensitive infections. Preclinical studies showed the efficacy of F12 does not diminish with repeated doses, while two other anti-MRSA lysin treatments currently in clinical trials are only designed to be used a single time.
“We have engineered this super potent, super effective anti-MRSA biotherapeutic, and we’ve done it in a way that renders it compatible with and largely invisible to the human immune system. By making it a safer drug, we’ve enabled the possibility of dosing multiple times in order to treat even the most highly refractory infections,” said Griswold.
The team’s paper, “Globally deimmunized lysostaphin evades human immune surveillance and enables highly efficacious repeat dosing,” was published earlier today by Science Advances. The work was the result of two grants from the National Institutes of Health (NIH) totaling $1.7 million.
The paper details the treatment’s positive results in rabbits, mice with partially-humanized immune systems, and studies with extracted human immune cells. Griswold believes the antibacterial agent could be ready for human clinical trials as soon as 2023.
“This is the first report of a translation-ready deimmunized lysin, and F12 has serious, bonafide clinical potential,” said Griswold.
Further studies of F12 will examine synergy with standard-of-care antibacterial chemotherapies. Preliminary results suggest the combinations are extremely potent and suppress drug-resistance phenotypes.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Drug resistant bacteria
- Chemicals working against superbug planon April 10, 2021 at 4:01 pm
Australia's plan for fighting antibiotic-resistant superbugs has failed to address a range of chemicals banned in the United States five years ago.
- Compounds in Amber Could Help Fight Drug-Resistant Bacteria Superbugs, Scientists Findon April 8, 2021 at 9:05 am
“We have now extracted and identified several compounds in Baltic amber that show activity against gram-positive, antibiotic-resistant bacteria.” Ambrose’s interest originally stemmed from her Baltic ...
- Prospective multicenter study on the incidence of surgical site infection after emergency abdominal surgery in Chinaon April 7, 2021 at 5:00 pm
There is still a lack of relevant studies on surgical site infection (SSI) after emergency abdominal surgery (EAS) in China. This study aims to understand the incidence of SSI after EAS in China and ...
- Supermarket pork, chicken contaminated by superbugs - studyon April 6, 2021 at 5:00 pm
WORLD ANIMAL PROTECTION-KENYA • Report showed high bacterial contamination of pork at 98.4 per cent and poultry at 96.6 per cent.• Contamination traced to antimicrobials used at farm level, not meat ...
- Paleopharmaceuticals Might Fight Drug-Resistant Infectionson April 6, 2021 at 6:25 am
"We have now extracted and identified several compounds in Baltic amber that show activity against gram-positive, antibiotic-resistant bacteria." Ambrose's interest originally stemmed from her Baltic ...
Go deeper with Google Headlines on:
Drug resistant bacteria
Go deeper with Bing News on:
F12 lysin-based antibacterial agent
- ContraFect Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Updateon March 30, 2021 at 9:23 am
Exebacase is a recombinantly-produced lysin (cell wall hydrolase enzyme ... a new class of DLAs which are recombinantly produced, antimicrobial proteins with a novel mechanism of action associated ...
- ContraFect Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Updateon March 30, 2021 at 4:33 am
YONKERS, N.Y., March 30, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents ...
- ContraFect Announces BARDA Contract Award for Up to $86.8 Million and Provides Business Outlookon March 11, 2021 at 1:54 pm
ContraFect expects to conduct an interim futility analysis to assess the superiority of exebacase versus SOC alone, based ... lysin with the potential to become the first direct lytic agent ...
- How I Treat: Feline Herpesviruson August 14, 2020 at 9:14 pm
Antiviral agents tend to be more toxic than do antibacterial agents since ... over the long term as a prophylactic measure. Based on recent experimental studies in which diets were supplemented with ...
- Beauty With a Conscience Awardson August 2, 2018 at 8:33 am
($22, 4 oz; talulahskincare.com) Burt's Bees Shaving Cream While it took some time to adjust from the foamy stuff to this emollient oil-based blend ... the amino acid L-lysine.